SCHEMBL6693792

SCHEMBL6693792

NC(=O)c1cccc2[nH]c3c(Cl)ccc(O)c3c12

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 1/20 0.43
AR P10275 1/20 0.41
PARP1 P09874 9/20 0.41
JAK2 O60674 2/20 0.41
DYRK1A Q13627 1/20 0.39
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 2/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
KMT2A Q03164 1/20 0.37
ATM Q13315 1/20 0.37
LMNA P02545 1/20 0.37
PIM1 P11309 1/20 0.36
PIM3 Q86V86 1/20 0.36
CHEK1 O14757 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8372849 0.82 BTK (0.45) PBRM1ARPARP1JAK2DYRK1A
SCHEMBL8373611 0.81 PARP1 (0.40) PBRM1ARPARP1JAK2DYRK1A
SCHEMBL8372827 0.77 PARP1 (0.40) PARP1KDM4EMAPTHPGDHSD17B10
SCHEMBL6694348 0.75 LMNA (0.43) PBRM1PARP1JAK2KDM4EMAPT
SCHEMBL8373691 0.74 PARP1 (0.41) PARP1JAK2
SCHEMBL8375950 0.74 PARP1 (0.37) PARP1JAK2KDM4EALDH1A1MAPT
SCHEMBL8374844 0.74 PARP1 (0.40) PARP1KDM4EALDH1A1MAPTHPGD
SCHEMBL8371587 0.74 CYP1A2 (0.39) PARP1KDM4EALDH1A1MAPTHPGD
SCHEMBL8371551 0.73 BTK (0.37) PARP1
SCHEMBL8372841 0.73 PARP1 (0.43) PARP1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP claimed
EP-0950657-B1 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors LILLY CO ELI (US) 2004-07-14 EP disclosed
EP-0952149-B1 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors LILLY CO ELI (US) 2004-06-09 EP disclosed
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed
EP-0950657-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors ELI LILLY AND COMPANY (US) 1999-10-20 EP disclosed